These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 22987973)

  • 1. Novel hormonal therapy for castration-resistant prostate cancer.
    Sternberg CN
    Ann Oncol; 2012 Sep; 23 Suppl 10():x259-63. PubMed ID: 22987973
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient?
    Tombal B
    Ann Oncol; 2012 Sep; 23 Suppl 10():x251-8. PubMed ID: 22987972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel and bone-targeted agents for CRPC.
    Fizazi K; Albiges L; Massard C; Escudier B; Loriot Y
    Ann Oncol; 2012 Sep; 23 Suppl 10():x264-7. PubMed ID: 22987974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone therapy in advanced prostate cancer.
    Forster TH; Stoffel F; Gasser TC
    Front Radiat Ther Oncol; 2002; 36():49-65. PubMed ID: 11842755
    [No Abstract]   [Full Text] [Related]  

  • 5. [Complete hormonal block vs. simple hormonal block in the treatment of carcinoma of the prostate].
    Berenguer Sánchez A
    Arch Esp Urol; 2002 Sep; 55(7):771-5. PubMed ID: 12380304
    [No Abstract]   [Full Text] [Related]  

  • 6. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy using LHRH and somatostatin analogues plus dexamethasone in androgen ablation refractory prostate cancer patients with bone involvement: a bench to bedside approach.
    Koutsilieris M; Bogdanos J; Milathianakis C; Dimopoulos P; Dimopoulos T; Karamanolakis D; Halapas A; Tenta R; Katopodis H; Papageorgiou E; Pitulis N; Pissimissis N; Lembessis P; Sourla A
    Expert Opin Investig Drugs; 2006 Jul; 15(7):795-804. PubMed ID: 16787142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients.
    Vaz S; Hadaschik B; Gabriel M; Herrmann K; Eiber M; Costa D
    Eur J Nucl Med Mol Imaging; 2020 Jan; 47(1):9-15. PubMed ID: 31654093
    [No Abstract]   [Full Text] [Related]  

  • 10. Endocrine therapy of prostate cancer.
    Bare RL; Torti FM
    Cancer Treat Res; 1998; 94():69-87. PubMed ID: 9587683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F; Dupont A; Belanger A
    Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel hormonal approaches in prostate cancer.
    Friedlander TW; Ryan CJ
    Curr Oncol Rep; 2009 May; 11(3):227-34. PubMed ID: 19336015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
    Rove KO; Crawford ED
    Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine treatment of prostate cancer: standard treatment and new perspectives.
    Boccardo F; Pace M
    In Vivo; 1993; 7(5):423-4. PubMed ID: 8110985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of secondary hormonal therapy in the management of recurrent prostate cancer.
    Ryan CJ; Small EJ
    Urology; 2003 Dec; 62 Suppl 1():87-94. PubMed ID: 14747046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].
    Pinto F; Calarco A; Totaro A; Sacco E; Volpe A; Racioppi M; D'Addessi A; Bassi PF
    Urologia; 2010; 77(2):71-83. PubMed ID: 20890863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined androgen blockade: the gold standard for metastatic prostate cancer.
    McLeod DG; Crawford ED; DeAntoni EP
    Eur Urol; 1997; 32 Suppl 3():70-7. PubMed ID: 9267789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hormone therapy in prostate cancer: clinical results].
    Morote-Robles J
    Rev Esp Fisiol; 1990 Mar; 46(1):59-62. PubMed ID: 1697693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The androgen receptor for the radiation oncologist.
    Quero L; Rozet F; Beuzeboc P; Hennequin C
    Cancer Radiother; 2015 May; 19(3):220-7. PubMed ID: 25921704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.